Moderate exacerbation was an exacerbation that required antibiotics or systemic gluticoricoids. Severe exacerbation was an exacerbation that led to hospitalisation or death
More efficacy data:
Discover lung function results >
See the health-related quality of life results >
Abbreviations:
BD, twice-daily; BUD, budesonide; CAT, COPD Assessment Test; COPD, chronic obstructive pulmonary disease; EXT, extension; FEV1, forced expiratory volume in one second; FF, fluticasone furoate; FOR, formoterol; ICS, inhaled corticosteroid; LABA, long-acting ß2-agonist; LAMA, long-acting muscarinic antagonist; NNT, number needed to treat; OD, once-daily; SGRQ, St George’s Respiratory Questionnaire; UMEC, umeclidinium; VI, vilanterol.
References:
- Lipson DA et al. N Engl J Med 2018; 378:1671–1680.
- Lipson DA et al. Am J Respir Crit Care Med 2017; 196(4):438–446.
- Lipson DA et al. N Engl J Med 2018; 378:1671–1680 (supplementary material).
- Lipson DA et al. N Engl J Med 2018; 378:1671–1680 (supplementary material protocol).
- TRELEGY Ellipta SmPC 2018, Available at www.medicines.ie [Accessed January 2020]
- Relvar Ellipta (fluticasone furoate/vilanterol 92/22 mcg) SmPC, 2018. Available at www.medicines.ie [Accessed January 2020]
- Anoro▼ Ellipta (umeclidinium/vilanterol 55/22 mcg) SmPC, 2018. Available at www.medicines.ie [Accessed January 2020]
TRELEGY Ellipta, Relvar Ellipta and Anoro Ellipta were developed in collaboration with INNOVIVA Inc.

Adverse events should be reported to the Health Products Regulatory Authority (HPRA) using an Adverse Reaction Report Form obtained either from the HPRA or electronically via the website at www.hpra.ie. Adverse reactions can also be reported to the HPRA by calling: (01) 6764971. Adverse events should also be reported to GlaxoSmithKline on 1800 244 255.
© 2019 GSK Group of Companies or its licensor. Trademarks are the property of their respective owners
TRELEGY Ellipta OD is indicated for maintenance treatment in adult patients with moderate-to-severe COPD who are not adequately treated by a combination of an ICS and a LABA, or a combination of a LAMA and a LABA 5
Relvar Ellipta is indicated for the symptomatic treatment of adults with COPD with a FEV1 <70% predicted normal (post-bronchodilator) with an exacerbation history despite regular bronchodilator therapy 6
Anoro Ellipta is indicated as a maintenance bronchodilator treatment to relieve symptoms in adult patients with COPD 7